Latest Regulatory Approvals News

Yancoal Australia is set to increase its ownership in the Moolarben Joint Venture from 95% to 98.75% through a $110.5 million acquisition, combining upfront and deferred payments linked to coal prices.

TAL Dai-ichi Life Australia has obtained all necessary regulatory approvals, including from APRA, to finalize its minority investment in Challenger Limited, acquiring a 19.9% equity stake.

Autosports Group is set to acquire Gulson Canberra, including the Porsche Centre Canberra, marking its entry into the Australian Capital Territory market and reinforcing its luxury brand strategy.

Energy Transition Minerals' subsidiary ETM Spain has been recommended as the preferred bidder for the Penouta Tin-Tantalum-Niobium mine in Galicia, Spain, marking a significant step in the company's expansion strategy.

Zenith Minerals has secured final Turkish regulatory approval for the sale of its Kavaklitepe Gold Project stake, unlocking approximately A$830,000 in cash proceeds. This milestone paves the way for the company to accelerate exploration at its core Australian gold assets.

Mount Hope Mining has received regulatory approval to commence its maiden drilling program at the Mt Hope Project, targeting three high-potential gold prospects in New South Wales.

MIXI Australia Pty Ltd has initiated an all-cash off-market takeover bid for PointsBet Holdings Limited at $1.20 per share, a significant premium recommended unanimously by the PointsBet Board. The offer promises certainty of cash consideration amid competing bids and regulatory conditions.

MIXI Australia has lodged a bidder’s statement for an all-cash $1.20 per share takeover offer for PointsBet Holdings Limited, with the PointsBet Board unanimously recommending acceptance in the absence of a superior proposal.

Silk Logistics Holdings has scheduled its shareholder meeting for August 1 to vote on the proposed $2.14 per share acquisition by DP World Australia, with an independent expert reaffirming the deal’s fairness.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Locksley Resources has confirmed multiple new mineralised trends at its Mojave Critical Minerals Project in California, setting the stage for an expanded drilling campaign in Q3 2025. The company’s detailed structural mapping and 3D geological modelling have refined exploration targets for antimony and rare earth elements, aligning with growing US strategic interests in domestic critical minerals.